Evan Hall

Assistant Professor, Medical Oncology, University of Washington, Division of Oncology, Seattle, Washington
Assistant Member, Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington


Dr. Hall’s research focus is on improving outcomes for patients receiving immunotherapy treatments, specializing in melanoma and kidney cancers. Dr. Hall has significant clinical experience in the use of immune checkpoint inhibitors as well as the management of side effects from these therapies. He leads several immunotherapy-based clinical trials at UW/Fred Hutch, in addition to quality-of-life and health services research. Some of Dr. Hall’s current research projects include: a multicenter study of physician‐patient communication surrounding checkpoint inhibitor therapies, a study of quality-of-life in cancer patients receiving checkpoint inhibitors, modeling of economic impact of alternative checkpoint inhibitor dosing strategies, and analyses of patterns of care and evaluation for potential health disparities in patients with metastatic melanoma or kidney cancer.

Dr. Hall has received numerous honors, most recently the 2019 Jonathan K. Cho, MD, and Cora Y. Cho Endowed Merit Award from the Conquer Cancer Foundation. Additionally, he has published >20 peer reviewed manuscripts (7 as first author or senior author).